Wellstar/TMI Announces Pending Pressure Ulcer Study on Leg and Foot Ulcers
14 Janvier 2009 - 11:03PM
Marketwired
Wellstar International, Inc. (OTCBB: WLSI), a provider of
specialized diagnostic software and equipment, announced today that
its wholly owned subsidiary, Trillennium Medical Imaging ("TMI"),
has begun negotiations for a pressure ulcer study focused on ulcers
caused by diabetic foot and venous legs. The Company is currently
in talks with several major teaching and research universities, the
goal of which is to secure a clinical partner for this study.
Wellstar anticipates that the study could start as early as March
2009.
In the U.S. alone, approximately 1.5 million adults are treated
each year for pressure ulcers (bedsores) with associated health
care costs of over $5 billion. Regrettably, more than 65,000
patients die each year from complications related to these ulcers.
Pressure ulcers represent one of four of the most common and costly
deficiencies found in long-term care facilities.
A diabetic foot ulcer is a sore or wound that often occurs in
people with diabetes; these ulcers may be difficult to heal,
susceptible to infection and may lead to amputation of the affected
toe, foot or leg if not treated. Over 850,000 chronic diabetic
ulcers are diagnosed in the U.S. each year. Approximately 3 million
diabetic patients will develop an ulcer and 25% of these patients
will have a foot amputated.
Venous leg ulcer is a sore or wound that is caused by poor
circulation of blood in the veins of the legs usually caused by
faulty valves allowing pressure to build up in the veins. This
pressure causes damage to the tiny blood vessels in the skin,
making the skin become thin and inflamed, and causing the death of
tissue cells leading to the ulcer.
The Company's infrared imaging system involves the detection and
recording of skin temperature and injury patterns, providing visual
and quantitative documentation to accurately capture body
temperature data. The Company's system map changes in skin blood
flow by translating temperature data into pictures. The
interpretation of these temperatures and thermal patterns can play
an important role in detecting these sores at an early stage.
Wellstar/TMI CEO John Antonio stated, "We are looking forward to
working with one of the clinical partners that we are currently
communicating with about this planned study. Early detection of
pressure ulcers is critical and can actually help prevent ulcer
outbreaks among patients. The TMI infrared imaging system is a
viable tool, and should soon prove to be the medical standard for
predicting and preventing pressure ulcers in the medical community.
"
ABOUT WELLSTAR INTERNATIONAL, INC.
Wellstar International, Inc., through its wholly owned operating
subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to
become a leading diagnostic company in the health care industry.
TMI has developed and is marketing fully calibrated and functional,
thermal imaging systems that utilize state-of-the-art infrared
technologies and proprietary software to accurately and
cost-effectively measure physiological changes in the human body.
More information on the Company and its unique diagnostic software
and product line is available on Wellstar's corporate Website by
visiting: www.wellstar.us
FORWARD-LOOKING STATEMENTS
This press release contains statements, which may constitute
'forward-looking statements' within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. Important
factors currently known to management that could cause actual
results to differ materially from those in forward-statements
include fluctuation of operating results, the ability to compete
successfully and the ability to complete before-mentioned
transactions. The company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
Contact: Equiti-trend Advisors LLC (800) 953-3350 Toll-Free,
U.S. & Canada (858) 436-3350 Local or International
Wellstar (CE) (USOTC:WLSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Wellstar (CE) (USOTC:WLSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024